Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in adult B-precursor ALL with minimal residual disease
2010-018314-75Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2010
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Primary endpoint: Complete minimal residual disease (MRD) response. Started Apr 2010; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2010-018314-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018314-75.